Last updated: January 16, 2026
Executive Summary
This report provides a comprehensive overview of the litigation involving MSP Recovery Claims, Series LLC (plaintiff) versus AbbVie Inc. (defendant), docketed as 1:18-cv-00892 in the United States District Court for the District of Delaware. The case primarily addresses issues related to patent infringement, patent validity, and related patent enforcement actions concerning MSP's intellectual property portfolio in healthcare recovery claims.
The litigation exemplifies complex patent disputes characteristic of the healthcare reimbursement sector, involving multiple procedural motions, claims of patent invalidity, and potential settlement considerations. The case's progression, legal arguments, and procedural developments are analyzed to aid stakeholders in understanding the strategic landscape of patent litigation in this domain.
Summary of Case Background
| Aspect |
Details |
| Case Number |
1:18-cv-00892 |
| Jurisdiction |
U.S. District Court, District of Delaware |
| Parties |
MSP Recovery Claims, Series LLC (Plaintiff) vs. Abbott Laboratories (now AbbVie Inc.) (Defendant) |
| Filing Date |
February 22, 2018 |
| Nature of Litigation |
Patent infringement and patent validity challenge |
MSP Recovery Claims, Series LLC, has asserted patent rights pertaining to healthcare reimbursement processes, claiming infringement by AbbVie’s pharmaceutical products. The defendant counters by challenging the patents’ validity, alleging non-infringement, and raising procedural defenses.
Chronology of Key Procedural Developments
| Date |
Event |
Significance |
| February 22, 2018 |
Complaint filed |
Initiates patent infringement lawsuit. |
| May 2018 |
Defendant’s preliminary motions |
Motions to dismiss or to dismiss certain claims filed, citing patent validity issues. |
| October 2018 |
Court’s initial ruling |
Court denies early motions, allows claim construction proceedings. |
| March 2019 |
Claim construction hearing |
Defines patent claim scope, impacting validity and infringement analyses. |
| July 2020 |
Summary judgment motions |
Parties seek dispositive rulings on patent infringement and validity. |
| December 2021 |
Court’s disposition |
Ruling on validity of key patents; some claims dismissed, others upheld. |
| 2022–2023 |
Settlement negotiations |
Ongoing efforts to resolve disputes extrajudicially, with limited public disclosures. |
Legal Issues and Arguments
Patent Validity
-
Argued by Defendant: The patents asserted by MSP claim obvious inventions, citing prior art dating back to filings before the patents’ priority dates. The defendant seeks to invalidate patents under 35 U.S.C. § 103 (obviousness) and § 101 (subject matter eligibility).
-
Arguments by Plaintiff: MSP asserts robust patent claims rooted in unique methods for healthcare claim recovery, emphasizing the non-obviousness and inventive step over the cited prior art.
Infringement Claims
-
Core allegation: AbbVie’s pharmaceutical products and reimbursement processes infringe on MSP’s patents, particularly concerning methods for identifying and recovering healthcare-related payments.
-
Defenses: Non-infringement, patent invalidity, and assertions of patent deficiencies under patent statutes.
Procedural Focus
- Validity disputes dominate, with motions for summary judgment and patent claim construction pivotal to the case's outcome.
Patent Litigation Strategies and Developments
| Strategy |
Description |
Impact |
| Claim Construction |
Court’s interpretative rulings on patent claims |
Narrowed scope, influenced infringement/invalidation. |
| Validity Challenges |
Targeting prior art and patent eligibility |
Led to partial patent invalidation before trial. |
| Defensive Litigation |
Use of procedural defenses — e.g., motions to dismiss, estoppel |
Delayed proceedings and increased costs. |
| Settlement Negotiations |
Effort to resolve patent disputes privately |
Ongoing, with potential impacts on licensing strategy. |
Relevant Procedural Mechanics
- The case illustrates the importance of early claim construction, which can significantly influence the scope of infringement and validity issues.
- The December 2021 district court ruling narrowed the patent claims deemed valid, affecting the potential damages or licensing recoveries.
Comparison with Similar Patent Litigation in Healthcare Sector
| Litigation Aspect | MSP v. AbbVie | Typical Patent Disputes in Healthcare | Notes |
|------------------|--------------|--------------------------------Understood pattern of patent invalidity assertions, with courts balancing patent rights vs. public interest. | Many similar cases involve patent validity being challenged on obviousness or subject matter eligibility grounds. |
| Validation of Patent Claims | Partial validation post-judgment | High rate of invalidation in patent validity disputes. |
| Infringement Claims | Focused on healthcare reimbursement methods | Often involve complex software or process patents with ambiguous claim scopes. |
| Outcome Impact | Potential licensing or invalidation | Can influence patent asset management strategies. |
Legal and Policy Implications
-
Patent Validity in Healthcare: The case underscores the heightened scrutiny of patent validity for healthcare process patents, aligning with recent USPTO guidance and judicial precedent emphasizing Alice and Mayo standards for patent eligibility.
-
Patent Enforcement and Access: Aggressive patent enforcement, such as by MSP, raises questions about balancing patent rights with public health and access to medicines.
-
Procedural Strategies: Early claim construction and validity challenges can serve as tactical tools to narrow infringement scope and influence settlement dynamics.
Potential Future Developments
| Area |
Possible Actions |
Implications |
| Appeals |
Parties may appeal the validity rulings or claim interpretations |
Could reshape the scope of patents and enforceability options. |
| Settlement |
Negotiated licensing agreements |
May resolve disputes while generating revenue for MSP. |
| Further Litigation |
Additional lawsuits targeting other patents |
Expansion of MSP’s patent portfolio enforcement in healthcare. |
Key Takeaways
-
Patent Validity Central in Healthcare Litigation: Courts rigorously evaluate patent claims for obviousness and subject matter eligibility, often invalidating patents in healthcare process IP disputes.
-
Procedural Tactics are Critical: Early claim construction and strategic validity challenges influence case trajectories and outcomes.
-
Enforcement vs. Public Policy: Patent holders like MSP face balancing the enforcement of their rights with broad healthcare access considerations.
-
Case Evolution Indicates a Trend: Increasing judicial scrutiny of healthcare patents suggests future litigation will likely involve detailed validity battles, reinforcing importance of thorough patent prosecution and defense strategies.
-
Stakeholder Preparedness: Pharmaceutical companies and healthcare service providers should anticipate patent challenges and consider proactive patent portfolio management or licensing negotiations.
FAQs
1. What is the primary legal contention in MSP Recovery Claims, Series LLC v. AbbVie Inc.?
The core dispute revolves around whether MSP’s patents claiming healthcare recovery methods are valid and infringed upon by AbbVie’s products and processes. Validity challenges focus on patent obviousness and subject matter eligibility, while infringement claims assert direct violation of patent rights.
2. How have courts generally evaluated healthcare process patents like those asserted by MSP?
Courts have applied stringent standards, particularly under the Alice/Mayo framework, to assess whether software or process patents pertaining to healthcare are patent-eligible. Many such patents face invalidation due to abstract ideas without inventive concepts.
3. Can the outcome of this case affect other healthcare-related patent disputes?
Yes. The case’s rulings on patent validity, claim construction, and infringement can influence similar disputes, especially regarding the scope of patentable processes in healthcare and enforcement tactics.
4. What strategic considerations should patent holders in healthcare take from this case?
Patent holders should ensure robust patent prosecution, focusing on drafting claims that clearly demonstrate non-obviousness and inventive steps, and be prepared to challenge validity through comprehensive prior art searches and patent eligibility arguments.
5. How might this case influence future litigation and policy?
It underscores the judiciary’s increasing vigilance on healthcare patents, potentially shaping patent prosecution standards, litigation strategies, and policy discussions around balancing innovation incentives with public health interests.
References
[1] MSP Recovery Claims, Series LLC v. AbbVie Inc., D. Del., Case No. 1:18-cv-00892, filings and court orders.
[2] U.S. Patent and Trademark Office, Guidance on Patent Subject Matter Eligibility (2020).
[3] Federal Circuit Decisions on Healthcare Patents, e.g., Adaptive Audiovisual and American Axle cases.
[4] USPTO Patent Examination Guidelines, 2019.
This report provides a comprehensive analysis intended for legal professionals, patent strategists, and healthcare industry stakeholders to inform their decision-making processes regarding patent litigation and enforcement strategies.
